Stanley M Chen Cardenas1,2, Prasanna Santhanam3. 1. Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Departamento de Medicina, Facultad de Medicina, Universidad de Panama, Panama City, Republic of Panama. 3. Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA. psantha1@jhmi.edu.
Abstract
BACKGROUND: Adrenal masses are commonly encountered in clinical practice, many of whom are incidental. Identifying malignancy, and excess hormone production is essential for appropriate management. Biochemical workup and imaging tests (dedicated adrenal CT and/or MRI) are used to determine the likelihood of excessive hormone function and malignancy, respectively. However, imaging cannot provide information about function and biochemical workup cannot localize the source. Furthermore, in primary aldosteronism, adrenal vein sampling, the gold standard for lateralization, has important limitations such as the technical expertise required, the elevated costs, and potential complications. Over the last decades, there has been a renewed interest in alternative noninvasive imaging techniques that provide information about adrenal function without the need for invasive procedures. In this review, we will evaluate the evidence and the potential role of 11C-metomidate as a promising positron emission tomography (PET) tracer in clinical practice. METHODS: A review of the English literature for articles describing the use of the tracer 11C-metomidate in adrenal disorders. RESULTS: A total of 12 studies were included in the systematic review, which altogether addressed the use of 11C-metomidate in adrenal masses and the application of this tracer in primary aldosteronism. CONCLUSIONS: 11C-metomidate, a selective inhibitor of 11-β-hydroxylase, demonstrated a high specificity for adrenocortical tissue. In addition, 11C-metomidate is correlated with this enzyme activity making it a potentially useful PET tracer for the identification primary aldosteronism, in addition to detection of adrenocortical masses.
BACKGROUND:Adrenal masses are commonly encountered in clinical practice, many of whom are incidental. Identifying malignancy, and excess hormone production is essential for appropriate management. Biochemical workup and imaging tests (dedicated adrenal CT and/or MRI) are used to determine the likelihood of excessive hormone function and malignancy, respectively. However, imaging cannot provide information about function and biochemical workup cannot localize the source. Furthermore, in primary aldosteronism, adrenal vein sampling, the gold standard for lateralization, has important limitations such as the technical expertise required, the elevated costs, and potential complications. Over the last decades, there has been a renewed interest in alternative noninvasive imaging techniques that provide information about adrenal function without the need for invasive procedures. In this review, we will evaluate the evidence and the potential role of 11C-metomidate as a promising positron emission tomography (PET) tracer in clinical practice. METHODS: A review of the English literature for articles describing the use of the tracer 11C-metomidate in adrenal disorders. RESULTS: A total of 12 studies were included in the systematic review, which altogether addressed the use of 11C-metomidate in adrenal masses and the application of this tracer in primary aldosteronism. CONCLUSIONS:11C-metomidate, a selective inhibitor of 11-β-hydroxylase, demonstrated a high specificity for adrenocortical tissue. In addition, 11C-metomidate is correlated with this enzyme activity making it a potentially useful PET tracer for the identification primary aldosteronism, in addition to detection of adrenocortical masses.
Authors: Martha A Zeiger; Geoffrey B Thompson; Quan-Yang Duh; Amir H Hamrahian; Peter Angelos; Dina Elaraj; Elliott Fishman; Julia Kharlip Journal: Endocr Pract Date: 2009 Jul-Aug Impact factor: 3.443
Authors: Dagmar E Ettlinger; Wolfgang Wadsak; Leonhard-Key Mien; Michael Machek; Leila Wabnegger; Gundula Rendl; Georgios Karanikas; Helmut Viernstein; Kurt Kletter; Robert Dudczak; Markus Mitterhauser Journal: Eur J Nucl Med Mol Imaging Date: 2006-05-11 Impact factor: 9.236
Authors: Stefanie Hahner; Michael C Kreissl; Martin Fassnacht; Heribert Haenscheid; Stefanie Bock; Frederik A Verburg; Pascal Knoedler; Katharina Lang; Christoph Reiners; Andreas K Buck; Bruno Allolio; Andreas Schirbel Journal: J Clin Endocrinol Metab Date: 2013-02-20 Impact factor: 5.958
Authors: John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young Journal: J Clin Endocrinol Metab Date: 2016-03-02 Impact factor: 5.958
Authors: Stefanie Hahner; Andrea Stuermer; Michael Kreissl; Christoph Reiners; Martin Fassnacht; Heribert Haenscheid; Felix Beuschlein; Martina Zink; Katharina Lang; Bruno Allolio; Andreas Schirbel Journal: J Clin Endocrinol Metab Date: 2008-04-08 Impact factor: 5.958
Authors: Gian Paolo Rossi; Richard J Auchus; Morris Brown; Jacques W M Lenders; Mitsuhide Naruse; Pierre Francois Plouin; Fumitoshi Satoh; William F Young Journal: Hypertension Date: 2013-11-11 Impact factor: 10.190